Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Signaling Properties of Structurally Diverse Kappa Opioid Receptor Ligands: Toward in Vitro Models of in Vivo Responses
Amelia Dunn, Brian Reed, Jose Erazo, et al.
ACS Chemical Neuroscience (2019) Vol. 10, Iss. 8, pp. 3590-3600
Closed Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Biased Opioid Ligands
Abdelfattah Faouzi, Balázs Varga, Susruta Majumdar
Molecules (2020) Vol. 25, Iss. 18, pp. 4257-4257
Open Access | Times Cited: 105
Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors
Despoina Aslanoglou, Suzanne Bertera, Marta Sánchez‐Soto, et al.
Translational Psychiatry (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 74
The Kappa Opioid Receptor: A Promising Therapeutic Target for Multiple Pathologies
Martin L. Dalefield, Brittany Scouller, Rabia Bibi, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 60
Design of κ-Opioid Receptor Agonists for the Development of Potential Treatments of Pain with Reduced Side Effects
Federica Santino, Luca Gentilucci
Molecules (2023) Vol. 28, Iss. 1, pp. 346-346
Open Access | Times Cited: 22
Strategies for DevelopingκOpioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects
Kelly F. Paton, Diana Vivian Atigari, Sophia Kaska, et al.
Journal of Pharmacology and Experimental Therapeutics (2020) Vol. 375, Iss. 2, pp. 332-348
Open Access | Times Cited: 45
A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse
Md Imdadul H. Khan, Benjamin J. Sawyer, Nicholas S. Akins, et al.
European Journal of Medicinal Chemistry (2022) Vol. 243, pp. 114785-114785
Open Access | Times Cited: 27
Identification and In Vivo Evaluation of Myelination Agent PIPE-3297, a Selective Kappa Opioid Receptor Agonist Devoid of β-Arrestin-2 Recruitment Efficacy
Thomas O. Schrader, Kym I. Lorrain, Didier Bagnol, et al.
ACS Chemical Neuroscience (2024) Vol. 15, Iss. 3, pp. 685-698
Closed Access | Times Cited: 4
Quantification of observable behaviors induced by typical and atypical kappa-opioid receptor agonists in male rhesus monkeys
Sally L. Huskinson, Donna M. Platt, Morgan Brasfield, et al.
Psychopharmacology (2020) Vol. 237, Iss. 7, pp. 2075-2087
Open Access | Times Cited: 32
Evaluation of Biased and Balanced Salvinorin A Analogs in Preclinical Models of Pain
Kelly F. Paton, Andrew Biggerstaff, Sophia Kaska, et al.
Frontiers in Neuroscience (2020) Vol. 14
Open Access | Times Cited: 30
Pharmacokinetics and Pharmacodynamics of Salvinorin A and Salvia divinorum: Clinical and Forensic Aspects
Andreia Machado Brito-da-Costa, Diana Dias da Silva, Nelson G. M. Gomes, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 2, pp. 116-116
Open Access | Times Cited: 26
An updated assessment of the translational promise of G-protein-biased kappa opioid receptor agonists to treat pain and other indications without debilitating adverse effects
Alexander R. French, Richard M. van Rijn
Pharmacological Research (2022) Vol. 177, pp. 106091-106091
Open Access | Times Cited: 18
Pharmacological Characterization of the Novel Selective Kappa Opioid Receptor Agonists 10-Iodo-Akuammicine and 10-Bromo-Akuammicine in Mice
Kathryn Bland, Chongguang Chen, Peng Huang, et al.
Neuropharmacology (2025), pp. 110316-110316
Closed Access
The G-protein biased kappa opioid agonists, triazole 1.1 and nalfurafine, produce non-uniform behavioral effects in male rhesus monkeys
Sally L. Huskinson, Donna M. Platt, C. Austin Zamarripa, et al.
Pharmacology Biochemistry and Behavior (2022) Vol. 217, pp. 173394-173394
Open Access | Times Cited: 16
Comparison of Pharmacological Properties between the Kappa Opioid Receptor Agonist Nalfurafine and 42B, Its 3-Dehydroxy Analogue: Disconnect between in Vitro Agonist Bias and in Vivo Pharmacological Effects
Danni Cao, Peng Huang, Yi-Ting Chiu, et al.
ACS Chemical Neuroscience (2020) Vol. 11, Iss. 19, pp. 3036-3050
Open Access | Times Cited: 23
Mechanisms Underlying the Anti-Suicidal Treatment Potential of Buprenorphine
Courtney M. Cameron, Steven J. Nieto, Lucienne Bosler, et al.
Advances in Drug and Alcohol Research (2021) Vol. 1
Open Access | Times Cited: 18
Preclinical Studies on Nalfurafine (TRK-820), a Clinically Used KOR Agonist
Yan Zhou, Kevin B. Freeman, Vincent Setola, et al.
Handbook of experimental pharmacology (2021), pp. 137-162
Open Access | Times Cited: 16
Morphinan Evolution: The Impact of Advances in Biochemistry and Molecular Biology
Keita Kajino, Akihisa Tokuda, Tsuyoshi Saitoh
The Journal of Biochemistry (2024) Vol. 175, Iss. 4, pp. 337-355
Open Access | Times Cited: 2
κ-Opioid receptor activation attenuates osteoarthritis synovitis by regulating macrophage polarization through the NF-κB pathway
Yi Shi, Huaqiang Tao, Xueyan Li, et al.
Acta Biochimica et Biophysica Sinica (2023)
Open Access | Times Cited: 6
Kappa Opioid Receptor Antagonists as Potential Therapeutics for Mood and Substance Use Disorders
Brian Reed, Eduardo R. Butelman, Mary Jeanne Kreek
Handbook of experimental pharmacology (2020), pp. 473-491
Closed Access | Times Cited: 16
Modulation of cocaine-related behaviors by low doses of the potent KOR agonist nalfurafine in male C57BL6 mice
Amelia Dunn, Kyle A. Windisch, Ariel Ben-Ezra, et al.
Psychopharmacology (2020) Vol. 237, Iss. 8, pp. 2405-2418
Closed Access | Times Cited: 15
The Role of the Kappa Opioid System in Comorbid Pain and Psychiatric Disorders: Function and Implications
Miao‐Jin Ji, Jiao Yang, Zhiqiang Gao, et al.
Frontiers in Neuroscience (2021) Vol. 15
Open Access | Times Cited: 13
Kappa-Opioid Receptor Blockade Ameliorates Obesity Caused by Estrogen Withdrawal via Promotion of Energy Expenditure through mTOR Pathway
Amparo Romero, Marta G. Novelle, Omar Al–Massadi, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 3118-3118
Open Access | Times Cited: 9
Signaling underlying kappa opioid receptor-mediated behaviors in rodents
Lee‐Yuan Liu‐Chen, Peng Huang
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 9
Design and development of novel, short, stable dynorphin-based opioid agonists for safer analgesic therapy
Rink‐Jan Lohman, Karnaker R. Tupally, Ajit Kandale, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 5
Contingent administration of typical and biased kappa opioid agonists reduces cocaine and oxycodone choice in a drug vs. food choice procedure in male rhesus monkeys
C. Austin Zamarripa, Sally L. Huskinson, E. Andrew Townsend, et al.
Psychopharmacology (2023) Vol. 241, Iss. 2, pp. 305-314
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top